Barusiban Subcutaneously for Reducing Implantation Failure Due to Uterine Contractions

Inclusion Criteria: * Women aged 18-37 years * Women who have undergone 2-4 previous fresh in vitro fertilization (IVF) or intracytoplasmatic sperm injection (ICSI) cycles that all resulted in a negative βhCG test, despite transfer of at least one embryo/blastocyst of good quality * Women who have in the current controlled ovarian stimulation cycle for IVF/ICSI followed the long Gonadotrophin Releasing Hormone (GnRH) agonist or GnRH antagonist protocol, received hCG for triggering of final follicular maturation and have undergone oocyte retrieval for IVF/ICSI with the purpose of fresh transfer * Retrieval of at least 6 oocytes in the current controlled ovarian stimulation cycle * Subjects should have at least one embryo of good quality available for transfer on day 3, or at least one good quality blastocyst available for transfer on day 5 Exclusion Criteria: * A total of 6 or more controlled ovarian stimulation cycles for IVF/ICSI * Abnormal karyotype * Uterine pathology or hydrosalpinx * Diagnosed with acquired or congenital thrombophilia disease